United Therapeutics Corp. (UTHR) announced Monday topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin (dinutuximab) Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory small cell lung cancer (SCLC).
from RTT - Biotech https://ift.tt/394F0QI
via IFTTT
No comments:
Post a Comment